Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Commercial
  • Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels
  • Commercial

Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels

Drug Channels

Today's guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Direct at GoodRx.

CommercialRead full story

pharminent April 24, 2026 (Last updated: April 24, 2026)

Drug Channels

Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Direct at GoodRx.

CommercialRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: OZMOSI and Planview partner to enhance pharmaceutical data integration
Next: Avalyn seeks public debut to support new lung drug formulations

Related Stories

  • Commercial

Lilly and Novo face off at ADA 2026 as others seek to compete in obesity

pharminent June 5, 2026
  • Commercial

CVS obesity drug deal puts Lilly on equal footing with Novo

pharminent May 28, 2026
  • Commercial

Kardigan targets IPO to support cardiology pipeline progression

pharminent May 27, 2026

You May Have Missed

  • Commercial

Lilly and Novo face off at ADA 2026 as others seek to compete in obesity

pharminent June 5, 2026
  • Market Access

Medicare Advantage in 2026: Enrollment Update and Key Trends

pharminent June 5, 2026
  • Policy / Pricing

The next FDA commissioner must be a champion for gene therapies

pharminent June 5, 2026
  • Clinical Data

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

pharminent June 5, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.